Clinical Trial Details
— Status: Not yet recruiting
Administrative data
NCT number |
NCT06316739 |
Other study ID # |
R34DA057166 |
Secondary ID |
|
Status |
Not yet recruiting |
Phase |
N/A
|
First received |
|
Last updated |
|
Start date |
May 2024 |
Est. completion date |
November 2025 |
Study information
Verified date |
March 2024 |
Source |
North Jersey AIDS Alliance dba North Jersey Community Research Initiative (NJCRI) |
Contact |
Honoria Guarino, PhD |
Phone |
347-581-2005 |
Email |
honoria.guarino[@]sph.cuny.edu |
Is FDA regulated |
No |
Health authority |
|
Study type |
Interventional
|
Clinical Trial Summary
The goal of this pilot clinical trial is to learn if an intervention that trains Gancheros
(people who provide injection services in exchange for drugs or money) to conduct
risk-reduction outreach could help lower risk for human immunodeficiency virus (HIV),
hepatitis C virus (HCV) and overdose among migrant Puerto Rican people who inject drugs
(PWID) in New York City. The main questions it aims to answer are:
- Can the Ganchero intervention be carried out successfully and will Gancheros and their
clients like it?
- Could the Ganchero intervention help Puerto Rican PWID who are clients of Gancheros use
sterile syringes and carry naloxone (a medication to reverse opioid overdoses) more
often?
Gancheros who participate in the trial will be asked to attend a 6-session training on HIV,
HCV, and overdose prevention and then to share key prevention messages and supplies (e.g.,
naloxone, sterile syringes and other injection equipment) with their clients during 4 months
of outreach. The intervention will be carried out with Gancheros and their clients in two
Bronx neighborhoods, one after the other, so the investigators can see if clients in the
neighborhood that received the intervention first have better outcomes than clients in the
neighborhood that did not yet receive the intervention.
Description:
The threat of human immunodeficiency virus (HIV) among people who inject drugs (PWID) in New
York City (NYC) is not over. Multiple HIV outbreaks among PWID in rural and urban areas of
the United States (US) have occurred recently, from 2015 in rural Indiana to 2018 in
northeastern Massachusetts. PWID who are racial/ethnic minorities continue to be
disproportionately infected with HIV. Among these, Puerto Rican (PR) PWID who started
injecting drugs in Puerto Rico and continue to inject drugs in NYC remain highly vulnerable
not only to HIV, but also to hepatitis C virus (HCV) and fatal opioid overdose. Analyses of
two different cycles of the National HIV Behavioral Surveillance (NHBS) study conducted by
the Centers for Disease Control and Prevention (CDC) in NYC found PR PWID, especially those
who migrated from Puerto Rico, to be the most HIV-vulnerable ethnic group. In 2017, the US
overdose mortality rate for US-born and Puerto Rico-born PR PWID exceeded the rate for
Non-Hispanic Whites, and the same holds true in NYC. Recent research showed that PR PWID
(both US- and Puerto Rico-born) have significantly higher prevalence of HCV than non-PR-PWID,
and that Puerto Rico-born migrant PWID have the highest HCV prevalence (86%) of all three
groups. Consequently, helping Puerto Rico-born PWID avoid HIV will help prevent HIV outbreaks
in NYC. Lowering their HCV and overdose risk will help reduce overall HCV prevalence (67%)
and overdose mortality rates (21.2 per 100,000) in NYC's PWID. Meeting these goals is urgent,
as PWID migration from Puerto Rico to NYC is ongoing, as evidenced by their sizeable (≥25%)
presence in NHBS studies in the past 15 years.
Risk behaviors of migrant PR PWID in the US are well documented. Compared to non-migrant
PWID, migrants regularly engage in syringe- and cooker-sharing. In NYC, PR migrants mostly
reside in the Bronx, the county with the largest numbers of PWID, overdose deaths, and new
cases of HIV, and very high HCV prevalence in PWID. In a recent National Institute for Drug
Abuse (NIDA)-funded ethnographic study (R03DA041892), the Principal Investigators identified
normative practices learned while injecting drugs in Puerto Rico as critical influences on
migrants' risks in NYC. These practices include: pervasive syringe-sharing after "cleaning"
syringes by "air-blowing and water-rinsing"; regular sharing and trading of heavily used
cookers which are highly valued for their concentrated drug residue; and low rates of
naloxone carriage despite frequent overdoses.
Grounded in a multi-level ecosocial framework, the proposed intervention will directly target
these practices by leveraging a key migrant PWID-role in NYC, the Ganchero: an "injection
doctor" who exchanges injection expertise for drugs or money. Because migrant PWID regularly
require expert injection services due to collapsed veins, Gancheros are central network
members well-positioned to promote positive health change. This is aligned with social
network diffusion theory, which underlies effective HIV prevention interventions that harness
peer influence by relying on PWID to disseminate risk-reduction messages in their networks.
PR migrant PWID are highly networked, and a peer-driven intervention relying on their network
ties promises to yield sustainable health behavior change. The investigators will develop and
conduct an initial evaluation of a Ganchero risk-reduction intervention for Puerto Rico-born
PWID that is effective, culturally appropriate, credible, and sustainable.
First, a multi-method, iterative process that will incorporate input from Gancheros and their
migrant clients will be used to develop the intervention: a training curriculum and outreach
protocol for Gancheros. Building on specific intervention recommendations developed in
consultation with a multiple-stakeholder Intervention Advisory Board and endorsed by focus
groups of migrant PWID in the investigators' prior study, the intervention will empower
Gancheros to promote and model consistent sterile syringe use and naloxone carriage with
their clients and in their PWID networks. Targeting two Bronx neighborhoods with high
proportions of PR migrants and non-overlapping PWID networks, the investigators will then
conduct a pilot clinical trial to evaluate the feasibility, acceptability, and preliminary
effectiveness of this innovative intervention.
Aim 1. Engage Gancheros (total n=4) and clients (total n=20) from both target neighborhoods
in a series of semi-structured interviews and focus groups to develop a risk-reduction
intervention comprised of a training curriculum and outreach protocol for Gancheros to
implement with their regular clients in real-world settings.
Aim 2. Conduct a pilot clinical trial using a wait-list control design with 10 Gancheros and
60 clients across the two target neighborhoods to evaluate the intervention's feasibility
(assessed via Ganchero and client participation rates), acceptability (assessed by Ganchero
and client Visual Analog Scale [VAS] ratings and qualitative feedback) and preliminary
effectiveness in increasing clients' rates of sterile syringe use (primary effectiveness
outcome) and naloxone carriage (secondary effectiveness outcome).
Structured assessments to measure these outcomes will be supplemented with data from
Gancheros' Weekly Outreach Reports and systematic ethnographic observations of Gancheros
deploying intervention strategies in the field to assess fidelity of implementation, barriers
encountered, and any pragmatic adaptations made in response to barriers, to inform future
refinement of the intervention and its implementation strategy.
Impact: A Ganchero-led intervention may help prevent HIV outbreaks among PWID in NYC and
mitigate the HCV and overdose syndemic among the highly vulnerable Puerto Rico-born PWID in
NYC. Results will inform a larger hybrid effectiveness-implementation trial to evaluate a
refined intervention for migrant PR PWID in NYC and other urban areas in the US with
significant numbers of at-risk migrants.